It collates data on health outcomes alongside laboratory results for virus tests. This creates a large and rich data platform, which will be used to accurately describe and predict health problems related to common viruses in the community.

The European 2025/26 influenza season is dominated by the influenza A(H3N2) virus, with most sequenced viruses belonging to subclade K, genetically drifted from the vaccine virus, raising concerns around vaccine effectiveness.

In a pre-season influenza risk assessment publicly posted in October 2025, Canadian investigators used global genomic and antigenic surveillance data to highlight important mutations in circulating influenza A(H3N2) viruses.

Both viral and host factors have contributed to the intensity of influenza activity during the 2025–2026 season. Some of these factors can be managed, whereas others are largely beyond human control.

In this self-controlled case series study of 11 887 patients, the risk of cardiorespiratory events after RSV-related hospitalization was significantly higher than during the control period.

Human influenza A viruses escape antibody-mediated immunity through changes in the hemagglutinin (HA) and neuraminidase (NA) glycoproteins.

Annual influenza epidemics in the United States cause hundreds of thousands of hospitalizations.

Global influenza and COVID-19 activity stayed low in late October 2025. COVID-19 was more common in northern regions, while influenza spread mainly in tropical areas.